Fresh from the biotech pipeline: fewer approvals, but biologics gain share
- PMID: 36624153
- PMCID: PMC9838261
- DOI: 10.1038/s41587-022-01630-6
Fresh from the biotech pipeline: fewer approvals, but biologics gain share
Abstract
2022 saw a 25% drop in new drug approvals and a less predictable regulator.
Figures
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources